Ocuphire Pharma, Inc.

OCUP

US67577R1023

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2024 BST			5-day change	1st Jan Change
2.06 ^USD	+4.83%		+32.05%	-31.56%

07-01	Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell Microcap Growth Index	CI
07-01	Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell 3000E Growth Index	CI

Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell Microcap Growth Index

July 30, 2024

Latest news about Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell Microcap Growth Index	06-30	CI
Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell 3000E Growth Index	06-30	CI
Ocuphire Pharma, Inc.(NasdaqCM:OCUP) added to Russell Microcap Value Index	06-30	CI
Ocuphire Pharma, Inc.(NasdaqCM:OCUP) added to Russell 3000E Value Index	06-30	CI
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June	06-06	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	04-11	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	04-11	CI
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study	04-11	CI
Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating	03-20	MT
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-08	CI
Ocuphire Pharma Appoints CFO, Science Chief	02-14	MT
Ocuphire Pharma, Inc. Announces Appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer	02-14	CI
Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer	02-14	CI
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy	02-05	CI
Ocuphire Pharma, Inc. Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity Under Dim Light Conditions	01-04	CI
Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023	12-06	CI
Transcript : Ocuphire Pharma, Inc., Q3 2023 Earnings Call, Dec 05, 2023	12-05
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer	11-27	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Ocuphire Pharma, Inc. Announces Successful End-Of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy	11-02	CI
Ocuphire Pharma Appoints George Magrath as Chief Executive	11-01	MT
Ocuphire Pharma, Inc. Appoints George Magrath as Member of Board of Directors	11-01	CI
Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes	11-01	CI
Viatris, Ocuphire Pharma Say US FDA Approves Eye Drops to Treat Pharmacologically-Induced Dilation of Pupils	27/09/23	MT

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Companyâs lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1Î± and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Companyâs pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ocuphire Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.06 USD

Average target price

19.33 USD

Spread / Average Target

+838.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OCUPHIRE PHARMA, INC.	-31.56%	53.4M
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+38.99%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.42%	244B
ROCHE HOLDING AG	+4.95%	234B
NOVARTIS AG	+16.22%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals